In a wider sense, the topic of pharmaceutical waste should be correctly extended, from an environmental point of view, to the field of pharmaceuticals and personal care products (PPCPs). By definition (US Environmental Protection Agency) PPCPs are any products used by individuals for personal health or cosmetic reasons or used by agribusiness to enhance the growth or health of livestock. PPCPs comprise a diverse collection of thousands of chemical substances, including prescription and over-the-counter therapeutic drugs, veterinary drugs, fragrances, and cosmetics. In particular, due to their inherent properties as biologically active agents either in humans or in a wide range of animals, the uncontrolled releases of pharmaceutical substances into the environment represent a serious health risk, as they may accumulate and stay active for a long time. A number of these substances meet the definition of hazardous waste according to the European Waste Catalogue and also the US Resource Conservation and Recovery Act (RCRA). Worldwide, as efforts to improve health in developing countries increase and ageing populations consume ever more medicines, there is a steady rising in the use of pharmaceuticals with a concomitant global growth in the generation of pharmaceutical waste.The presence of therapeutic drugs, hormones, and other organic contaminants in surface waters has been widely recognized in all industrialized countries as a consequence of improper disposal of PPCPs. This however represents a concern even in developing countries where often armed conflicts and natural disasters can leave such ill-equiped countries with the challenge of disposing of large quantities of expired pharmaceuticals donated as part of humanitarian aid. Therefore, in such emergencies, the safe disposal of unwanted or expired drugs can create a major problem that international agencies should take into account when carrying out assistance to the local communities.
When focusing on pharmaceuticals as a waste management problem two main streams of these wastes should be considered: (1) pharmaceutical products, namely unused, unneeded, or expired prescription drugs intended for and used by people in their homes and in primary care treatment faciliites, and drugs used to treat domestic pets and commercial livestock; and (2) pharmaceutical waste (with the exclusion of both infectious medical and low-level radioactive waste) generated at pharmacies, hospitals and other healthcare establishments either for humans or for animals (which can differ in nature, volume, and potency); these might arise from unused/unwanted drugs to non-contaminated medicine packages (that are simply non-hazardous municipal waste), to pharmaceutical substance residues and expired drugs which are similar in nature to those of domestic origin.
In a long-term environmental perspective as well as from an eco-toxicological point of view, attention should be given to what the European Environment Agency recommends in its Technical Report No 1/2010 on Pharmaceuticals in the Environment. Clearly, this document suggests a ' . . . more comprehensive environmental stewardship of pharmaceuticals across their full life cycles'. This means the need to look ' . . . at pre-production issues (including raw materials and energy), secondary manufacturing, and the impact of drugs and their breakdown products when they enter the environment'. In fact, the mitigation of negative environmental footprints may only be achieved ' . . . By broadening the analysis of environmental impacts to include the full life cycle . . . and by identifying hot spots . . . (which can help to develop) . . . ways to avoid especially harmful or inefficient activities.' That disposal problems start with the waste produced during the manufacturing of the active pharmaceutical ingredients (APIs) is a matter of fact. Thereafter, throughout the life cycle of different pharmaceutical products, the active ingredients can contribute to enlarge the pharmaceutical waste volume by cross-contaminating a variety of materials. As a consequence, waste streams that include pharmaceuticals pose critical technical and/or economic issues on both urban wastewater treatment plants and household waste management systems.
Excreted medications and their metabolites along with pharmaceuticals which are discharged into the sewerage system contribute to the presence of at least trace if not more significant medicine residues in wastewater. As pharmaceuticals are designed to be resistant to biodegradation and current technology at the majority of wastewater treatment plants is unable to remove most APIs, ecosystems are thus exposed to these pollutants. Moreover, people who rely on API-contaminated surface water as a source of drinking water can, in turn, suffer possible detrimental effects from the unintended injestion of drugs. Dramatic negative impacts on aquatic species and human health can occur especially when wastewater includes antibiotics or endocrine disruptors (i.e. those chemicals that mimic natural hormones) even in small amounts. Furthermore, whereas sewage sludge left over after the treatment of wastewater is largely land-applied worldwide as agricultural fertilizer, as a soil amendment in disturbed site reclamation, as an additive in composting mixtures, or as landfill cover, the presence of PPCPs in biosolids should be assessed in order to prevent soil contamination, even if not regulated in previous directives. Therefore, future US and EU legislation on the land application of biosolids may become more comprehensive along with new scientific evidence and advancements in analytical technology related to pharmaceutical residues. Of course, this kind of pollution due to medical or veterinary treatments cannot be avoided to a significant extent in the short term as the design of new pharmaceutical formulations that reduce or eliminate the release of hazardous substances may only be expected over the long term. In the meantime, the mitigation of wastewater contamination by pharmaceutical residues can be harnessed through more efficient treatments such as UV-based processes or intensive oxidation methods capable of destroying these organic compounds.
Although water quality has generated great interest in pharmaceutical waste management, the original concern for proper strategies in residential pharmaceutical waste management remains relevant. Since the 1970s, with the first experiences in Sweden, the most creditable method of handling household pharmaceutical waste, albeit still inefficiently applied even in industrialized countries, is the activation of 'take-back' programmes which entail the return by consumers of unwanted or expired medicines to special containers at the pharmacies. Collected pharmaceuticals are then sent off-site for processing, typically by incineration. It is necessary, however, for the incineration to be carried out within regulated plants that have been designed for this purpose in order to achieve sufficiently high combusion temperatures and to meet limit values on the emissions to the atmosphere. In fact, incomplete or improper incineration can pose serious risks for air pollution and, in turn, potential health problems. On the other hand, delivery of such waste to landfills should generally be avoided due to possible hazards of leaching into groundwater or APIs building up in leachate to be then pumped out from the landfill beds and sent to wastewater treatment plants. Nevertheless, whereas in the EU incinerators are widely available for pharmaceutical waste management, in the USA and most developing countries landfilling remains the main option for the disposal of such waste.
Management of consistent amounts of unwanted pharmaceuticals from pharmacies, hospitals, and clinics requires a different approach. In this case, the so-called 'reverse distribution' of pharmaceuticals could play a strategic role with pharmaceutical manufactures offering credits for returned medicines. Although manufacturers may process returned drugs for reuse, most returned pharmaceuticals are currently sent offsite for disposal. Nevertheless this collection system would have to be promoted, or implemented where it is already functioning, since pharmaceuticals sent to manufacturers through reverse distributors are considered 'products' of economic value and thus are not 'waste', with evident implications for the rules to be followed and the costs to be sustained in managing such materials. As unwanted residential pharmaceuticals must be disposed of, without any possibility of recycling, the 'reverse distribution' system would not be suitable in this case.
On the basis of these considerations, collection programmes at both local pharmacies and healthcare establishments, as well as processing via incineration, seem to be the most reliable steps in the management of pharmaceutical waste. Ultimately, strategies that reduce either the volume of the PPCPs and/or their harmful nature may be more beneficial and efficacious to society in the long run instead of trying to change the current disposal methods for unused/ unwanted medicines. Solutions to reduce pharmaceutical waste streams may include, among others: (a) the reduction of unused drugs through more tailored dosing (i.e. shorter dispensing cycles) and package size (i.e. smaller packs); (b) improving public awareness of both health hazards and adverse environmental impacts of pharmaceutical preparations by more appropriate labelling; (c) encouraging more cautious prescriptions of medicines; and (d) implementing pharmaceutical take-back programmes with or without a specific waste management fee, although this could lead some to use unsuitable methods of disposal to avoid the cost.
Pharmaceuticals remain the tip of an iceberg of concern in the municipal waste management field, so this is one of many distress signals to all concerned to avoid significant environment impairment.
